Akums Drugs and Pharmaceuticals Ltd., a Contract Development and Manufacturing Organization (CDMO), has announced the launch of Doxylamine + Pyridoxine extended-release tablets, a therapy approved by the CSDCO (Central Drugs Standard Control Organization), India and the United States Food and Drug Administration (USFDA). This marks a milestone as a therapy in India, with a [patent application in process]. Akums’ inventive solution aims to tackle the issues by integrating Doxylamine and Pyridoxine into extended-release tablets.
Bionpharma's Generic Doxylamine Succinate, Pyridoxine Hydrochloride
Enforcement Report - Week Of June 01, 2022
Enforcement Report - Week of February 9, 2022
The US Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion (OPDP) on Monday said that it’s working on two studies, one of which will focus on Instagram influencers and how people perceive what they say.
Alliance Pharmaceuticals Ltd has informed us that the Patient Information Leaflet (PIL) is missing the possible side effects from post-marketing experience and the associated class effects that are documented in the Summary of Product Characteristics (SmPC).
Enforcement Report - Week of August 14, 2019
Enforcement Report - Week of June 19, 2019
The national drug pricing regulator National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 22 formulations under Drugs Prices Control Order (DPCO), 2013 in related notification dated May 02, 2019.